AIMS: To investigate the ability of SYNTAX score and Clinical SYNTAX score (CSS) to predict very long-term outcomes in an all-comers population receiving drug-eluting stents. METHODS AND RESULTS: The SYNTAX score was retrospectively calculated in 848 patients enrolled in the SIRolimus-eluting stent compared withpacliTAXel-Eluting Stent for coronary revascularization (SIRTAX) trial. The CSS was calculated using age, and baseline left ventricular ejection fraction and creatinine clearance. A stratified post hoc comparison was performed for all-cause mortality, cardiac death, myocardial infarction (MI), ischaemia-driven target lesion revascularization (TLR), definite stent thrombosis, and major adverse cardiac events (MACE) at 1- and 5-year follow-up. Tertiles for SYNTAX score and CSS were defined as SS(LOW) ≤ 7, 7< SS(MID) ≤ 14, SS(HIGH) >14 and CSS(LOW) ≤ 8.0, 8.0 <CSS(MID) ≤ 17.0 and CSS(HIGH) >17.0, respectively. Major adverse cardiac events rates were significantly higher in SS(HIGH) compared with SS(LOW) at 1- and 5-year follow-up, which was also seen at 5 years for all-cause mortality, cardiac death, MI, and TLR. Stratifying outcomes across CSS tertiles confirmed and augmented these results. Within CSS(HIGH), 5-year MACE increased with use of paclitaxel- compared with sirolimus-eluting stents (34.7 vs. 21.3%, P = 0.008). SYNTAX score and CSS were independent predictors of 5-year MACE; CSS was an independent predictor for 5-year mortality. Areas-under-the-curve for SYNTAX score and CSS for 5-year MACE were 0.61 (0.56-0.65) and 0.62 (0.57-0.67), for 5-year all-cause mortality 0.58 (0.51-0.65) and 0.66 (0.59-0.73) and for 5-year cardiac death 0.63 (0.54-0.72) and 0.72 (0.63-0.81), respectively. CONCLUSION: SYNTAX score and to a greater extent CSS were able to stratify risk for very long-term adverse clinical outcomes in an all-comers population receiving drug-eluting stents. Predictive accuracy for 5-year all-cause mortality was improved using CSS. TRIAL REGISTRATION NUMBER: NCT00297661.
RCT Entities:
AIMS: To investigate the ability of SYNTAX score and Clinical SYNTAX score (CSS) to predict very long-term outcomes in an all-comers population receiving drug-eluting stents. METHODS AND RESULTS: The SYNTAX score was retrospectively calculated in 848 patients enrolled in the SIRolimus-eluting stent compared with pacliTAXel-Eluting Stent for coronary revascularization (SIRTAX) trial. The CSS was calculated using age, and baseline left ventricular ejection fraction and creatinine clearance. A stratified post hoc comparison was performed for all-cause mortality, cardiac death, myocardial infarction (MI), ischaemia-driven target lesion revascularization (TLR), definite stent thrombosis, and major adverse cardiac events (MACE) at 1- and 5-year follow-up. Tertiles for SYNTAX score and CSS were defined as SS(LOW) ≤ 7, 7< SS(MID) ≤ 14, SS(HIGH) >14 and CSS(LOW) ≤ 8.0, 8.0 <CSS(MID) ≤ 17.0 and CSS(HIGH) >17.0, respectively. Major adverse cardiac events rates were significantly higher in SS(HIGH) compared with SS(LOW) at 1- and 5-year follow-up, which was also seen at 5 years for all-cause mortality, cardiac death, MI, and TLR. Stratifying outcomes across CSS tertiles confirmed and augmented these results. Within CSS(HIGH), 5-year MACE increased with use of paclitaxel- compared with sirolimus-eluting stents (34.7 vs. 21.3%, P = 0.008). SYNTAX score and CSS were independent predictors of 5-year MACE; CSS was an independent predictor for 5-year mortality. Areas-under-the-curve for SYNTAX score and CSS for 5-year MACE were 0.61 (0.56-0.65) and 0.62 (0.57-0.67), for 5-year all-cause mortality 0.58 (0.51-0.65) and 0.66 (0.59-0.73) and for 5-year cardiac death 0.63 (0.54-0.72) and 0.72 (0.63-0.81), respectively. CONCLUSION: SYNTAX score and to a greater extent CSS were able to stratify risk for very long-term adverse clinical outcomes in an all-comers population receiving drug-eluting stents. Predictive accuracy for 5-year all-cause mortality was improved using CSS. TRIAL REGISTRATION NUMBER: NCT00297661.
Authors: D Y Sahin; M Gür; Z Elbasan; N Y Koyunsever; C Türkoğlu; S Akyol; A Yıldırım; G Gözübüyük; B Ozaltun; M Caylı Journal: Herz Date: 2013-03-14 Impact factor: 1.443
Authors: Christoph Sinning; Elvin Zengin; Christoph Waldeyer; Moritz Seiffert; Renate B Schnabel; Edith Lubos; Tanja Zeller; Christoph Bickel; Stefan Blankenberg; Peter M Clemmensen; Dirk Westermann Journal: Clin Res Cardiol Date: 2016-06-30 Impact factor: 5.460
Authors: Ernest Spitzer; Martina Frei; Serge Zaugg; Susanne Hadorn; Henning Kelbaek; Miodrag Ostojic; Andreas Baumbach; David Tüller; Marco Roffi; Thomas Engstrom; Giovanni Pedrazzini; Vladan Vukcevic; Michael Magro; Ran Kornowski; Thomas F Lüscher; Clemens von Birgelen; Dik Heg; Stephan Windecker; Lorenz Räber Journal: J Am Heart Assoc Date: 2017-08-05 Impact factor: 5.501
Authors: Philippe Généreux; Tullio Palmerini; Adriano Caixeta; Gregg Rosner; Philip Green; Ovidiu Dressler; Ke Xu; Helen Parise; Roxana Mehran; Patrick W Serruys; Gregg W Stone Journal: J Am Coll Cardiol Date: 2012-04-04 Impact factor: 24.094
Authors: Christoph Sinning; Lars Lillpopp; Sebastian Appelbaum; Francisco Ojeda; Tanja Zeller; Renate Schnabel; Edith Lubos; Annika Jagodzinski; Till Keller; Thomas Munzel; Christoph Bickel; Stefan Blankenberg Journal: Clin Res Cardiol Date: 2013-03-23 Impact factor: 5.460